09.09.12
Neuroendocrine Tumors: Update on Somatostatin Analogues
 |
| 111In-pentetreotide scintigraphy of the 41 year-old man with ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neuroendocrine tumor became clearly visible in 4/2005 (arrow). (Photo credit: Wikipedia) |
Power injectable peripherally inserted central venous catheters (PICC) flip after power injection
 |
| Chest X-ray showing tip of PICC line in the Superior Vena Cava (Photo credit: Wikipedia) |
PICC
 |
| A typical peripherally inserted central catheter. The maker's logo has been intentionally painted out. This is a single lumen model, but they are also available in two and three lumen models. (Photo credit: Wikipedia) |
- ARROW
- GROSHONG
PÉČE
zásady: asepticky, stříkačky 10 ml
návrat krve 4-5 ml
proplach: F1/1 10 ml ( před a po aplikaci léku )
F1/1 20 ml po odběru krve
- při proplachu používat techniku 'push-pause' - po každém ml roztoku udělat pauzu - vznikající turbulence umožní snadnější proplach a zabraňuje ucpávání katetru
- snaha zachování pozitivního tlaku na konci katetru - při posledním aplikovaném ml zasvorkovat
zátka: HEPARINOVÁ ZÁTKA pouze pro ARROW PICC
- při opakovaném používání v průběhu dne - jen F1/1 10ml
- při používání po více jak 1 dni - heprinová zátka 5 ml s HEPARINEM 10j/ml ( delší nepoužívání katetru udává 100j/ml )
Frekvence výkonů:
- převaz krytí po zavedení za 1-3 dny - při používání 1x za 7 dnů (transparentní krytí)
Fixace katetru Stat-Lock
Odkazy:
ARROW - Peripheral catheter - Nursing care guidelines ( pdf.)
Video
The FDA have recently warned about the cardiac effect of a 32 mg single intravenous (IV) dose of ondansetron
Doporučení k aplikaci ondansetronu:
max. 0,15 mg\/kg každé 4 hodiny max tři dávky; však žádná jednotlivá intravenózní dávka nesmí překročit 16 mg.
Comparison of catheter-related large vein thrombosis in centrally inserted versus peripherally inserted central catheters
CONCLUSIONS: In neurological critical care patients, CICVCs appear to have a better risk profile compared to PICCs, with a decreased risk of CRLVT. As use of PICCs in critical care patients increases, a prospective randomized trial comparing PICCs and CICVCs in neurological critical care patients is necessary to assist in choosing the appropriate catheter and to minimize risks of morbidity and mortality associated with central venous access.
05.09.12
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial | DocGuide
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial | DocGuide
Subcutaneous trastuzumab, administered over about 5 min, has a pharmacokinetic profile and efficacy non-inferior to standard intravenous administration, with a similar safety profile to intravenous trastuzumab, and therefore offers a valid treatment alternative.
Subcutaneous trastuzumab, administered over about 5 min, has a pharmacokinetic profile and efficacy non-inferior to standard intravenous administration, with a similar safety profile to intravenous trastuzumab, and therefore offers a valid treatment alternative.
Přihlásit se k odběru:
Příspěvky (Atom)